- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.09. | FDA will review abortion pill safety - will it be impartial? | ||
| 26.09. | BMS adds discounted psoriasis drug to its DTC channel | ||
| 26.09. | Lilly brings second oral SERD to market for breast cancer | ||
| 26.09. | Shock as Trump says 100% pharma tariffs will start on 1 Oct | ||
| 25.09. | Biolinq bags FDA okay for autonomous glucose sensor | ||
| 25.09. | Merck names electronics unit head to replace Garijo as CEO | ||
| 25.09. | Verona Pharma shareholders back $10bn MSD takeover | ||
| 25.09. | AZ takes Medicare negotiation appeal to SCOTUS | ||
| 25.09. | Acadia, Harmony record late-stage rare disease failures | ||
| 25.09. | Moderna opens UK facility as drug pricing spat rumbles on | ||
| 24.09. | Joy as uniQure Huntington's therapy clears pivotal trial | ||
| 24.09. | BMS eyes filings for myeloma 'celmod' iberdomide | ||
| 24.09. | MSD's $345m alliance with Variational, and other AI news | ||
| 24.09. | FDA knocks back Biogen's high-dose Spinraza | ||
| 24.09. | Lilly names Houston as site for $6.5bn API facility | ||
| 23.09. | Manufacturing issues block FDA nod for Scholar Rock SMA drug | ||
| 23.09. | Roche's oral SERD comes good in 2nd-line breast cancer trial | ||
| 23.09. | Angelini taps Sovargen for epilepsy drug in $550m deal | ||
| 23.09. | BMS says it will set Cobenfy's UK price the same as the US | ||
| 23.09. | Alarm as Trump peddles unproven causes of autism | ||
| 22.09. | After internal setbacks, Pfizer buys obesity player Metsera | ||
| 22.09. | Bayer starts pivotal Parkinson's cell therapy trial | ||
| 22.09. | Stealth's patience rewarded as FDA approves Barth drug | ||
| 22.09. | FDA clears subcutaneous Keytruda in a boost to MSD | ||
| 19.09. | Breaking: ACIP pushes back vote on hepatitis B vaccine |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .